Allogene Therapeutics, Inc. (ALLO)
| Market Cap | 217.48M -26.1% |
| Revenue (ttm) | 4.64M |
| Net Income | -174.46M |
| EPS | -0.61 |
| Shares Out | 346.47M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,870,359 |
| Open | 0.6420 |
| Previous Close | 0.6669 |
| Day's Range | 0.6192 - 0.6700 |
| 52-Week Range | 0.6192 - 4.4600 |
| Beta | 0.78 |
| Analysts | Strong Buy |
| Price Target | 9.00 (+1,333.81%) |
| Earnings Date | Nov 5, 2026 |
About ALLO
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for ALLO stock is "Strong Buy." The 12-month stock price target is $9.0, which is an increase of 1,333.81% from the latest price.
News
Allogene Therapeutics to Host Events at American Society of Hematology Annual Meeting 2026 Highlighting the Potential of Allogeneic CAR T to Expand Patient Access
SOUTH SAN FRANCISCO, Calif., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...
Allogene Therapeutics Transcript: Jefferies Global Healthcare Conference
ALPHA3ās April 2026 interim showed MRD clearance of 58% with cema-cel vs 16% with observation and a clean outpatient safety profile. An EFS interim is assumed for mid-2027, with the primary analysis assumed in 2028.
Allogene Therapeutics Transcript: UBS Global Biopharma Conference 2026
ALPHA3 showed MRD conversion in 58% of cema-cel patients versus 2/12 under observation, with an interim analysis expected mid-2027 and full enrollment by end-2027. ALLO-329 showed symptom improvement in diffuse cutaneous scleroderma without lymphodepletion.
Allogene Therapeutics reports clinical data from RESOLUTION study
Allogene Therapeutics (ALLO) announced preliminary safety, efficacy and translational data from the ongoing Phase 1 RESOLUTION study evaluating ALLO-329, an investigational, next-generation, off-the-s...
Allogene Therapeutics Transcript: Study update
In Phase I RESOLUTION, 18 patients received ALLO-329; no dose-limiting toxicities or grade 3+ CRS were reported. Among 10 scleroderma patients, 8 achieved and maintained a clinically meaningful mRSS improvement, including patients treated without lymphodepletion.
Allogene Therapeutics Press release: Study update
Allogene Therapeutics issued a press release on November 9, 2026, disclosing material business information to investors.
Allogene Therapeutics Slides: Study update
Allogene Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on November 9, 2026.
Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune Disease
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...
Allogene Therapeutics reports Q3 EPS (15c), consensus (14c)
Reports Q3 revenue $0, consensus $2.22k. āWe believe 2027 will be an important year for cema-cel and the field, with upcoming ALPHA3 data expected to provide important insights into theā¦
Allogene Therapeutics Earnings Call Transcript: Q3 2026
ALPHA3 enrollment is accelerating, with completion targeted by year-end 2027 and a mid-year update planned. ALLO-329ās upcoming data will test its safety and activity across conditioning regimens, including reduced or no lymphodepletion.
Allogene Therapeutics Earnings release: Q3 2026
Allogene Therapeutics released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Allogene Therapeutics Quarterly report: Q3 2026
Allogene Therapeutics has published its Q3 2026 quarterly earnings report on November 5, 2026.
Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...
Allogene Therapeutics Slides: Corporate presentation
Allogene Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on November 5, 2026.
Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...
Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...
Allogene Therapeutics participates in a conference call with JPMorgan
Conference call with management will be held on October 21 at 2 pm hosted by JPMorgan. Webcast Link
Allogene Therapeutics Transcript: Citigroupās Biopharma Back to School Summit 2026
Key programs cema-cel and ALLO-329 are advancing, with strong interim data and broadening MRD testing adoption. Commercial launch planning is underway, with cema-cel positioned to expand CAR T access and address a large market. Financial runway extends into 2029, supporting upcoming catalysts.
Allogene Therapeutics management to meet with Piper Sandler
Meeting to be held on September 8 hosted by Piper Sandler.
Allogene Therapeutics CFO Geoffrey Parker to retire
Allogene Therapeutics (ALLO) announced that Geoffrey Parker, executive VP and CFO, will retire effective November 6. Parker will continue to lead the finance organization through his retirement date a...
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC...
Allogene Therapeutics Announces Participation in September Investor Conference
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...
Allogene Therapeutics files $500M mixed securities shelf
16:24 EDT Allogene Therapeutics (ALLO) files $500M mixed securities shelf
Allogene Therapeutics reports Q2 EPS (13c), consensus (15c)
Reports Q2 revenue $4.64M, consensus $2,220. āWhen we reset our strategy in 2024, we started with the patient and focused on where the distinct attributes of allogeneic CAR T couldā¦